ADC Therapeutics (ADCT) Expected to Post Earnings on Tuesday

ADC Therapeutics (NYSE:ADCT) will likely be announcing its Q3 2026 results before the market opens on Tuesday, November 10th. Analysts expect ADC Therapeutics to post earnings of ($0.21) per share and revenue of $18.69 million for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Monday, November 9, 2026 at 8:30 AM ET.

ADC Therapeutics (NYSE:ADCT) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.11. The firm had revenue of $19.25 million for the quarter, compared to analyst estimates of $18.89 million. On average, analysts expect ADC Therapeutics to post ($0.80) EPS for the current fiscal year and ($0.76) EPS for the next fiscal year.

ADC Therapeutics Stock Up 2.3%

Shares of ADCT stock traded up $0.04 on Tuesday, reaching $1.57. The stock had a trading volume of 233,066 shares, compared to its average volume of 1,362,866. The firm’s 50-day moving average is $1.31 and its two-hundred day moving average is $2.47. The firm has a market capitalization of $201.08 million, a price-to-earnings ratio of -2.40 and a beta of 1.86. ADC Therapeutics has a 12 month low of $0.78 and a 12 month high of $4.98.

Analyst Ratings Changes

A number of equities analysts recently commented on ADCT shares. Guggenheim reduced their price target on ADC Therapeutics to $5.00 and set a “buy” rating for the company in a report on Monday, August 17th. Weiss Ratings restated a “sell (d-)” rating on shares of ADC Therapeutics in a research note on Thursday, October 15th. Finally, Wall Street Zen raised ADC Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Three investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, ADC Therapeutics has an average rating of “Hold” and a consensus price target of $5.00.

ADC Therapeutics Company Profile

ADC Therapeutics SA (NYSE: ADCT) is a biotechnology company focused on developing and commercializing antibody-drug conjugates (ADCs) for the treatment of cancer. Its ADC platform is designed to combine monoclonal antibodies that target specific tumor-associated antigens with potent cytotoxic payloads, with the goal of selectively delivering treatment to cancer cells while limiting exposure to healthy tissue.

The company’s lead product is Zynlonta (loncastuximab tesirine-lpyl), an ADC directed against the CD19 antigen.